SOMATIC MUTATIONS AT THE GLYCOPHORIN A LOCUS IN RADIATION EXPOSED INDIVIDUALS

以血糖素A为基础的体细胞有两个主要目标 突变分析项目。第一个目标是确定 由血吸虫病引起的个体体细胞突变损伤的程度和类型 切尔诺贝利核电事故的辐射暴露，由 血糖素A(GPA)测定。将对来自以下地点的样品进行分析 有高剂量和中剂量暴露的个人，将包括 半合子N0和纯合子NN频率的测定 变异的红细胞。体细胞频率的测量 GPA基因的突变将与不同的指标相关 来自该计划项目中其他计划的基因损害提供了 对这些个体的遗传损伤进行综合分析。 第二个目标是确定GPA检测作为一种 用于大群体个体研究的生物剂量计 剂量学信息不可用。剂量效应的测量 关系、最小可检测剂量和诱发的持久性 损伤将被用来确定GPA检测剂量的效用 评估。GPA检测结果将与 从计划项目中的其他生物剂量计中确定相对 不同方法的灵敏度、成本和可靠性。

There are two primary objectives for the glycophorin A-based somatic mutation analysis project. The first objective is to determine the magnitude and types of somatic mutational damage in individuals due to radiation exposure from the Chernobyl nuclear power accident as measured by the glycophorin A (GPA) assay. Analysis will be performed on samples from individuals with both high- and moderate-dose exposures, and will include measurements of the frequency of both hemizygous N0 and homozygous NN variant erythrocytes. Measurements of the frequencies of somatic cell mutations at the GPA locus will be correlated with different indicators of genetic damage from other programs in the program project to provide a comprehensive analysis of genetic damage in these individuals. The second objective is to determine the utility of the GPA assay as a biodosimeter for large population studies of individuals where physical dosimetry information is not available. Measurements of the dose-response relationship, the minimum detectable dose, and the persistence of induced damage will be used to determine the utility of the GPA assay for dose assessment. Results from the GPA assay will be compared with the results from other biodosimeters in the program project to determine the relative sensitivity, cost, and reliability of the different methods.